First Eagle Investment Management’s PDL BioPharma, Inc. PDLI Stock Holding History

First Eagle Investment Management’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-2,800	Closed	-$8K	–	335
2017 Q4	$8K	Hold	2,800	–	–	﹤0.01%	319
2017 Q3	$9K	Hold	2,800	–	–	﹤0.01%	335
2017 Q2	$7K	Hold	2,800	–	–	﹤0.01%	318
2017 Q1	$6K	Hold	2,800	–	–	﹤0.01%	312
2016 Q4	$6K	Hold	2,800	–	–	﹤0.01%	316
2016 Q3	$9K	Hold	2,800	–	–	﹤0.01%	332
2016 Q2	$9K	Hold	2,800	–	–	﹤0.01%	341
2016 Q1	$9K	Hold	2,800	–	–	﹤0.01%	323
2015 Q4	$10K	Hold	2,800	–	–	﹤0.01%	316
2015 Q3	$14K	Hold	2,800	–	–	﹤0.01%	301
2015 Q2	$18K	Hold	2,800	–	–	﹤0.01%	295
2015 Q1	$20K	Hold	2,800	–	–	﹤0.01%	309
2014 Q4	$22K	Hold	2,800	–	–	﹤0.01%	312
2014 Q3	$21K	Hold	2,800	–	–	﹤0.01%	311
2014 Q2	$27K	Hold	2,800	–	–	﹤0.01%	298
2014 Q1	$23K	Hold	2,800	–	–	﹤0.01%	364
2013 Q4	$24K	Hold	2,800	–	–	﹤0.01%	349
2013 Q3	$22K	Hold	2,800	–	–	﹤0.01%	333
2013 Q2	$22K	Buy	+2,800	New	+$21.8K	﹤0.01%	325

Other funds holding PDLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

First Eagle Investment Management's PDLI Position: Q1 2018 in Review

First Eagle Investment Management sold out of PDL BioPharma, Inc. (PDLI) in Q1 2018, closing a stake of 2,800 shares — an estimated $8K sold.

First Eagle Investment Management first reported a position in PDLI in Q2 2013 and held it in 19 quarters. The position peaked at $27K in Q2 2014. 176 funds tracked by Wall St. Rank hold PDLI as of Q1 2018.

First Eagle Investment Management reported no remaining PDL BioPharma, Inc. position as of Q1 2018 after selling out during the quarter.
First Eagle Investment Management sold 2,800 PDL BioPharma, Inc. shares in Q1 2018, an estimated $8K.
First Eagle Investment Management first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 19 quarters.
First Eagle Investment Management's PDL BioPharma, Inc. position peaked at $27K in Q2 2014.
176 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2018.

Based on First Eagle Investment Management's 13F filing for Q1 2018, filed 4 May 2018.